Role of minimally invasive surgery versus open approach in patients with early-stage uterine carcinosarcomas: a retrospective multicentric study.


Journal

Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 18 07 2020
accepted: 19 08 2020
pubmed: 4 9 2020
medline: 25 2 2021
entrez: 4 9 2020
Statut: ppublish

Résumé

The aim of this retrospective study was to compare surgical and survival outcome in only patients with early-stage UCSs managed by laparotomic surgery (LPT) versus minimally invasive surgery (MIS). Data were retrospectively collected in four Italian different institutions. Inclusion criteria were UCS diagnosis confirmed by the definitive histological examination, and stage I or II according to the FIGO staging system. Between August 2000 and March 2019, the data relative to 170 patients bearing UCSs were collected: of these, 95 were defined as early-stage disease (stage I-II) based on the histological report at the primary surgery, and thus were included in this study. Forty-four patients were managed by LPT, and 51 patients were managed by MIS. The operative time was lower in the MIS group versus the LPT group (p value 0.021); the median estimated blood loss was less in the MIS group compared to the median of LPT group (p value < 0.0001). The length of hospital stay days was shorter in the MIS patients (p value < 0.0001). Overall, there were eight (8.4%) post-operative complications; of these, seven were recorded in the LPT group versus one in the MIS group (p value 0.023). There was no difference in the disease-free survival (DFS) and overall survival (OS) between the two groups. There was no difference of oncologic outcome between the two approaches, in face of a more favourable peri-operative and post-operative profile in the MIS group.

Identifiants

pubmed: 32880752
doi: 10.1007/s00432-020-03372-x
pii: 10.1007/s00432-020-03372-x
pmc: PMC7873090
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

845-852

Références

Lancet Oncol. 2010 Aug;11(8):772-80
pubmed: 20638899
J Minim Invasive Gynecol. 2017 Mar - Apr;24(3):438-445
pubmed: 28065812
Oncology. 2018;95(2):100-108
pubmed: 29791913
Cancers (Basel). 2019 Jul 09;11(7):
pubmed: 31324031
J Clin Oncol. 2009 Nov 10;27(32):5331-6
pubmed: 19805679
Gynecol Oncol. 2017 Aug;146(2):405-415
pubmed: 28566221
Eur J Cancer. 2016 Sep;65:185-91
pubmed: 27505629
Gynecol Oncol. 2013 Apr;129(1):38-41
pubmed: 23321065
Int J Gynecol Cancer. 2018 Feb;28(2):254-259
pubmed: 29303931
Gynecol Oncol. 2008 Oct;111(1):82-8
pubmed: 18674808
Gynecol Oncol. 2017 Apr;145(1):71-77
pubmed: 28317560
Int J Gynaecol Obstet. 2009 May;105(2):109
pubmed: 19345353
Gynecol Oncol. 2016 Dec;143(3):460-465
pubmed: 27743738
Int J Gynecol Cancer. 2016 Jan;26(1):2-30
pubmed: 26645990
Eur J Cancer. 2017 Jul;79:81-89
pubmed: 28463759
Int J Gynecol Pathol. 2019 May;38(3):205-215
pubmed: 30958427
Gynecol Oncol. 2015 Jun;137(3):581-8
pubmed: 25805398
J Korean Med Sci. 2017 Nov;32(11):1891-1895
pubmed: 28960047
Geburtshilfe Frauenheilkd. 2016 Feb;76(2):188-193
pubmed: 26941453
JAMA. 2017 Mar 28;317(12):1224-1233
pubmed: 28350928
Ann Oncol. 2010 May;21 Suppl 5:v41-5
pubmed: 20555100
Arch Gynecol Obstet. 2010 Dec;282(6):659-64
pubmed: 20721670
J Gynecol Oncol. 2018 Mar;29(2):e22
pubmed: 29400015
Oncology. 2006;71(5-6):333-40
pubmed: 17690557
Ann Oncol. 2009 May;20 Suppl 4:29-31
pubmed: 19454455
Curr Opin Oncol. 2019 Sep;31(5):411-419
pubmed: 31261170
Gynecol Oncol. 2010 Mar;116(3):419-23
pubmed: 19896181
J Clin Oncol. 2016 Dec 10;34(35):4225-4230
pubmed: 27903150
J Minim Invasive Gynecol. 2017 May - Jun;24(4):531-532
pubmed: 27794476
Ann Surg Oncol. 2016 Jan;23(1):196-202
pubmed: 25994210
Oncol Res Treat. 2018;41(11):675-679
pubmed: 30317231
Eur J Cancer. 2012 May;48(8):1147-53
pubmed: 22548907
Gynecol Oncol. 2012 Aug;126(2):180-5
pubmed: 22555102
Gynecol Oncol. 2006 Dec;103(3):948-51
pubmed: 16870239
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Lancet Oncol. 2008 Mar;9(3):297-303
pubmed: 18308255

Auteurs

Giacomo Corrado (G)

Department of Woman, Child Health and Public Health, Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy. giacomo.corrado@alice.it.

Francesca Ciccarone (F)

Department of Woman, Child Health and Public Health, Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.

Francesco Cosentino (F)

Department of Gynecologic Oncology, Gemelli Molise Spa, Università Cattolica del Sacro Cuore, Campobasso, Italy.

Francesco Legge (F)

Gynecologic Oncology Unit, "F. Miulli" General Regional Hospital, Acquaviva Delle Fonti, Bari, Italy.

Andrea Rosati (A)

Department of Woman, Child Health and Public Health, Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.

Martina Arcieri (M)

Department of Woman, Child Health and Public Health, Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.

Luigi Carlo Turco (LC)

Department of Gynecologic Oncology, Gemelli Molise Spa, Università Cattolica del Sacro Cuore, Campobasso, Italy.
Department Gynecology and Breast Care Unit, Mater Olbia Spa, Olbia, Italy.

Camilla Certelli (C)

Department of Experimental Clinical Oncology, Gynecologic Oncology Unit, "Regina Elena" National Cancer Institute, IRCCS, Rome, Italy.

Alex Federico (A)

Department of Woman, Child Health and Public Health, Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.

Enrico Vizza (E)

Department of Experimental Clinical Oncology, Gynecologic Oncology Unit, "Regina Elena" National Cancer Institute, IRCCS, Rome, Italy.

Francesco Fanfani (F)

Department of Woman, Child Health and Public Health, Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
Istituto di Ostetricia e Ginecologia, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.

Giovanni Scambia (G)

Department of Woman, Child Health and Public Health, Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
Istituto di Ostetricia e Ginecologia, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.

Gabriella Ferrandina (G)

Department of Woman, Child Health and Public Health, Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
Istituto di Ostetricia e Ginecologia, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH